ODONATE ODO-TE-B301 (CONTESSA TRIO OLDER ADULTS)
A Multicenter, Phase 2 Study of Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Elderly Patients With HER2 Negative MBC
Breast, Metastatic Breast Cancer, MBC,
Odonate Therapeutics, Inc.
Key Eligibility Criteria Details
- Age 65 or older
- Locally advanced breast cancer not considered curable by surgery or radioation or metastatic breast cancer
- Measurable Disease
- Brain mets are allowed
- ECOG PS 0-2
- If ER/PR+, must have received prior therapy with endocrine therapy (+/- CDK 4/6 therapy).
- Any number of prior endocrine or targeted therapies are permitted
- No prior chemotherapy for metastatic disease
- No known HIV/HBV/HCV
- No Grade >1 neuropathy